Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 1;118(2):354-359.
doi: 10.14309/ajg.0000000000002053. Epub 2022 Oct 11.

Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease

Matthew D Egberg  1   2 , Xian Zhang  1 , Andrew B Smitherman  3   4 , Michael D Kappelman  1   2
Affiliations

Low Risk of Lymphoma in Pediatric Patients Treated for Inflammatory Bowel Disease

Matthew D Egberg et al. Am J Gastroenterol. .

Abstract

Introduction: Despite the effectiveness of immune-suppressing therapies in treating pediatric inflammatory bowel diseases (IBDs), concerns of lymphoma may limit their use. We used a large administrative claims database to evaluate the risk of lymphoma in pediatric IBD and conducted a case series analysis of medication exposure in children diagnosed with lymphoma.

Methods: We analyzed administrative claims from the 2007 to 2018 IQVIA database and identified pediatric (≤18 years) patients with Crohn's disease or ulcerative colitis using International Classification of Diseases, 9th or 10th Revision codes and pharmacy claims. Lymphoma cases were identified by diagnosis codes and confirmed by independent claim-by-claim review by a pediatric oncologist and gastroenterologist. We calculated incidence rates for lymphoma among patients with and without pharmacy claims for treatment followed by treatment description among those who developed lymphoma during follow-up.

Results: A total of 10,777 pediatric patients with IBD received ≥1 IBD therapy (median age 15 years [12-17], 45% female and 61% diagnosed with Crohn's disease) during 28,292 patient-years of follow-up. Among treated patients, 5 lymphoma cases were identified (incidence rate 17.7/100,000 patient-years; 95% confidence interval 6.5-39.2). Of these, 4 were treated with a thiopurine before lymphoma diagnosis, and none received anti-tumor necrosis factor-α (anti-TNF) monotherapy.

Discussion: The overall lymphoma incidence was low among our cohort of treated pediatric patients with IBD. We observed no cases of lymphoma among patients prescribed anti-TNF monotherapy. These findings reinforce the relative safety of anti-TNF monotherapy for the treatment of pediatric IBD.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: MDK has consulted for Abbvie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm.

Comment in

References

    1. Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22(8):36. doi:10.1007/s11894-020-00773-3 - DOI - PMC - PubMed
    1. Ferrante M, Van Assche G. Medical therapy and mucosal healing. Curr Drug Targets 2012;13(10):1294–1299. doi:10.2174/138945012802429679 - DOI - PubMed
    1. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011;52(1):31–37. doi:10.1097/MPG.0b013e3181edd797 - DOI - PubMed
    1. Scott FI, Johnson FR, Bewtra M, et al. Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn’s Disease. Inflamm Bowel Dis 2019;25(5):925–936. doi:10.1093/ibd/izy321 - DOI - PubMed
    1. Bewtra M, Fairchild AO, Gilroy E, et al. Inflammatory bowel disease patients’ willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol 2015;110(12):1675–1681. doi:10.1038/ajg.2015.321 - DOI - PubMed

Publication types

Substances